Current through Chapters 1 to 249 and Chapters 253 to 255 of the 2024 Legislative Session
Section 176B:4JJ - [See also Version 2 as added by a different 2016 act] Coverage for long-term antibiotic therapy for patients with Lyme disease(a) For the purposes of this section, "long-term antibiotic therapy" and "Lyme disease" shall have the meaning ascribed to them in section 12DD of chapter 112.(b) A subscription certificate under an individual or group medical service agreement delivered, issued or renewed within the commonwealth shall provide coverage for long-term antibiotic therapy for a patient with Lyme disease when determined to be medically necessary and ordered by a licensed physician after making a thorough evaluation of the patient's symptoms, diagnostic test results or response to treatment. An experimental drug shall be covered as a long-term antibiotic therapy if it is approved for an indication by the United States Food and Drug Administration; provided, however, that a drug, including an experimental drug, shall be covered for an off-label use in the treatment of Lyme disease if the drug has been approved by the United States Food and Drug Administration.Mass. Gen. Laws ch. 176B, § 4JJ
Added by Acts 2016, c. 183,§ 3, eff. 7/1/2016.